Artisan Partners Limited Partnership Sells 23,544 Shares of Repligen Co. (NASDAQ:RGEN)

Artisan Partners Limited Partnership decreased its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 5.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 413,747 shares of the biotechnology company's stock after selling 23,544 shares during the quarter. Artisan Partners Limited Partnership owned approximately 0.74% of Repligen worth $59,555,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in RGEN. Signaturefd LLC lifted its stake in shares of Repligen by 172.2% during the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock worth $28,000 after buying an additional 124 shares during the last quarter. Resources Management Corp CT ADV bought a new position in Repligen in the 3rd quarter valued at about $37,000. Quarry LP raised its holdings in Repligen by 796.7% in the 3rd quarter. Quarry LP now owns 269 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 239 shares during the period. UMB Bank n.a. lifted its position in Repligen by 49.1% during the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 110 shares during the last quarter. Finally, Global Retirement Partners LLC boosted its holdings in shares of Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 129 shares during the period. 97.64% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on RGEN. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Friday, February 21st. Evercore ISI started coverage on Repligen in a report on Tuesday, March 18th. They set an "in-line" rating and a $155.00 target price for the company. Royal Bank of Canada upped their price target on shares of Repligen from $203.00 to $205.00 and gave the company an "outperform" rating in a research note on Friday, February 21st. TD Cowen started coverage on shares of Repligen in a research note on Monday, February 10th. They issued a "buy" rating and a $200.00 price objective for the company. Finally, Canaccord Genuity Group started coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price on the stock. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $178.64.

Repligen Trading Up 1.0 %

NASDAQ:RGEN traded up $1.26 during mid-day trading on Tuesday, hitting $128.50. 748,822 shares of the company's stock were exchanged, compared to its average volume of 676,999. The firm has a market capitalization of $7.22 billion, a P/E ratio of -251.96, a PEG ratio of 4.54 and a beta of 0.95. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $182.52. The company has a 50 day simple moving average of $152.75 and a 200-day simple moving average of $148.00.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, research analysts expect that Repligen Co. will post 1.72 earnings per share for the current year.

Insider Activity

In related news, Director Margaret Pax purchased 250 shares of Repligen stock in a transaction on Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now owns 1,043 shares of the company's stock, valued at $157,169.67. This trade represents a 31.53 % increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by company insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.